This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Cubist Pharmaceuticals (CBST) shares sank Thursday after the stock was downgraded by research firm JMP Securities to market outperform from buy, citing a lack of near-term catalysts.

Biotech analyst Adam Cutler says the stock is cheap, however, and that "sales trends have been healthy, and there should be plenty of growth left." Cutler lowered his price target on the stock to $24 from $28. Shares fell 3.2% to $17.62.

Shares of Quest Diagnostics (DGX - Get Report) lost 1.2% to $50.46 after the lab specialist guided lower for 2007.

The diagnostic test outfit earned $151 million, or 77 cents a share, in the fourth quarter, above analysts' estimates of 74 cents a share. Revenue grew 8.5% to $1.55 billion. Analysts expected revenue of $1.57 billion. For 2007, the company expects earnings of between $2.70 and $3 a share on $6 billion to $6.2 billion in revenue. Analysts were expecting earnings of $3.21 a share on sales of $6.4 billion for the year.

St. Jude Medical's (STJ - Get Report) shares rose 4.3% to $41.37 Thursday after the medical device maker reported an increase in fourth-quarter earnings and issued guidance for growth in 2007.

The company earned $155 million, or 42 cents a share, including a retroactive benefit of approximately 3 cents a share related to a research and development tax credit for the first nine months of 2006. Analysts were expecting the company to earn 39 cents a share. Sales were $864 million, up more than 9% from the fourth quarter of 2005 and exceeding analysts' estimates of $852.35 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARTX $3.63 0.28%
BMY $71.96 -0.30%
CBST $101.94 0.14%
CYTX $0.30 -6.28%
DGX $75.15 -0.03%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs